Suppr超能文献

一种用于在人类神经元中创建可扩展表型筛选测定的简单方法。

A Simple Procedure for Creating Scalable Phenotypic Screening Assays in Human Neurons.

机构信息

The Scripps Research Molecular Screening Center, Department of Molecular Medicine, Scripps Research, Jupiter, Florida, 33458, USA.

Department of Neuroscience, Scripps Research, Jupiter, Florida, 33458, USA.

出版信息

Sci Rep. 2019 Jun 21;9(1):9000. doi: 10.1038/s41598-019-45265-1.

Abstract

Neurons created from human induced pluripotent stem cells (hiPSCs) provide the capability of identifying biological mechanisms that underlie brain disorders. IPSC-derived human neurons, or iNs, hold promise for advancing precision medicine through drug screening, though it remains unclear to what extent iNs can support early-stage drug discovery efforts in industrial-scale screening centers. Despite several reported approaches to generate iNs from iPSCs, each suffer from technological limitations that challenge their scalability and reproducibility, both requirements for successful screening assays. We addressed these challenges by initially removing the roadblocks related to scaling of iNs for high throughput screening (HTS)-ready assays. We accomplished this by simplifying the production and plating of iNs and adapting them to a freezer-ready format. We then tested the performance of freezer-ready iNs in an HTS-amenable phenotypic assay that measured neurite outgrowth. This assay successfully identified small molecule inhibitors of neurite outgrowth. Importantly, we provide evidence that this scalable iN-based assay was both robust and highly reproducible across different laboratories. These streamlined approaches are compatible with any iPSC line that can produce iNs. Thus, our findings indicate that current methods for producing iPSCs are appropriate for large-scale drug-discovery campaigns (i.e. >10e compounds) that read out simple neuronal phenotypes. However, due to the inherent limitations of currently available iN differentiation protocols, technological advances are required to achieve similar scalability for screens that require more complex phenotypes related to neuronal function.

摘要

由人类诱导多能干细胞 (hiPSC) 产生的神经元提供了识别潜在大脑疾病生物机制的能力。源自 IPSC 的人类神经元(iNs)有望通过药物筛选推进精准医疗,尽管目前尚不清楚 iNs 在多大程度上能够支持工业规模筛选中心的早期药物发现工作。尽管已经有几种方法可以从 iPSC 中生成 iNs,但每种方法都存在技术限制,这影响了它们的可扩展性和可重复性,这是成功筛选测定的两个要求。我们通过最初消除与高通量筛选 (HTS) 就绪测定相关的 iNs 规模化的障碍来解决这些挑战。我们通过简化 iNs 的生产和接种并将其适用于冷冻就绪格式来实现这一目标。然后,我们在一种可用于 HTS 的表型测定中测试了冷冻就绪 iNs 的性能,该测定测量了神经突生长。该测定成功地鉴定了神经突生长的小分子抑制剂。重要的是,我们提供的证据表明,这种可扩展的基于 iN 的测定既稳健又在不同实验室之间具有高度可重复性。这些简化的方法与任何可以产生 iNs 的 iPSC 系兼容。因此,我们的研究结果表明,目前用于产生 iPSC 的方法适合于大规模的药物发现活动(即 >10e 种化合物),这些方法可以读取简单的神经元表型。然而,由于目前可用的 iN 分化方案存在固有限制,需要技术进步来实现对与神经元功能相关的更复杂表型的筛选的类似可扩展性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b2d/6588600/61536affc944/41598_2019_45265_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验